Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials

Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials

BackgroundCancer, with sustained high mortality, is a worldwide threat to public health. Despite the survival benefit over conventional therapies shown in immune checkpoint inhibitor (ICI), only a minority of patients benefit from single ICI. But combination therapy holds the promise of achieving be...

Full description

Bibliographic Details
Main Authors: Leyin Zhang, Leitao Sun, Yiwen Zhou, Jieru Yu, Yingying Lin, Harpreet S. Wasan, Minhe Shen, Shanming Ruan
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitor
combination therapy
cancer
efficacy
immune-related adverse events
systematic review and meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.575457/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.575457/full

Similar Items